Metabolic and cardiovascular disease patients have increased plasma levels of lipids and,
specifically, of palmitate, which can be toxic for several tissues. Trimetazidine (TMZ), a …

Trimetazidine (TMZ) is used successfully for treatment of ischemic cardiomyopathy, however
its therapeutic potential in heart failure (HF) remains to be established. While the …

Trimetazidine is an anti-ischemic drug whose cytoprotective mechanisms are not yet fully
understood (but until now mainly related to the trimetazidine-induced “metabolic shift” from …

Background and Purpose Trimetazidine, known as a metabolic modulator, is an anti‐anginal
drug used for treatment of stable coronary artery disease (CAD). It is proposed to act via …

Objective: Myocardial ischemia affects mitochondrial functions, leading to ionic imbalance
and susceptibility to ventricular fibrillation. Trimetazidine, a metabolic agent, is clinically …

Myocardial ischemia affects mitochondrial function leading to ionic imbalance and
susceptibility to ventricular fibrillation. Trimetazidine (TMZ), a metabolic agent, is clinically …

Trimetazidine (TMZ) is an anti-ischemic compound devoid of hemodynamic effects. It was
recently suggested to induce cardiomyocyte protection by a mechanism involving lipid …

Palmitate, a C16 fatty acid found in high concentrations in the blood in acute myocardial
infarction, induces apoptotic cell death. To more completely define the nature and …

The mechanism of action of the antianginal trimetazidine (TMZ) remains largely unknown. In
cultured rat ventricular myocytes in physiologic conditions, TMZ (5× 10− 4M) reduced the …

Obesity induces skeletal muscle dysfunction. The pathogenesis of which appears to
substantially involve mitochondrial dysfunction, arising from impaired quality control …